Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
Healthcare
$4.48 -1.44%
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
52W Low $2.52High $13.67
Volume 1.05M
Average 0.94M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$153.71M
FY 2025 · Annual
Investing Cash Flow
$40.02M
FY 2025 · Annual
Financing Cash Flow
$141.17M
FY 2025 · Annual
-58.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.8M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.25M | 929K | 2.22M | 8.36M | 10.08M |
| Change in Working Capital | (4.49M) | (10.33M) | 3.42M | 7.86M | (1.08M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 11K | 677K | 4.08M | 736K | 543K |
| Other Working Capital | (4.5M) | (11M) | (659K) | 7.12M | (1.62M) |
| Other Non-Cash Items | 850K | 1.13M | 605K | (5.12M) | (3.21M) |
| Operating Cash Flow | (22.16M) | (36.11M) | (52.41M) | (114.25M) | (153.71M) |
| Capital Expenditures | (1.29M) | (768K) | (621K) | (2.21M) | (5K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 70K |
| Purchases of Investments | 0 | (56.5M) | (54.85M) | (490M) | (364.62M) |
| Sales of Investments | 0 | 43.17M | 46.68M | 323.64M | 398.81M |
| Other Investing Activities | 0 | 0 | 0 | 7.66M | 5.76M |
| Investing Cash Flow | (1.29M) | (14.1M) | (8.79M) | (160.9M) | 40.02M |
| Debt Repayment | (41K) | (249K) | (781K) | (956K) | 23.89M |
| Common Stock Issued | 0 | 0 | 0 | 341.17M | 117.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 30K | 175K | (1M) | (3.1M) | (144K) |
| Financing Cash Flow | 72.52M | 11.88M | 58.12M | 337.11M | 141.17M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 49.08M | (38.33M) | (3.08M) | 61.96M | 27.47M |
| Free Cash Flow | (23.44M) | (36.88M) | (53.03M) | (116.46M) | (153.72M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$161.3M
+ D&A$1.8M
+ Stock-Based Comp$10.1M
+ Deferred Tax$0
- Working Capital-$1.1M
- Other Non-Cash-$3.2M
= Operating Cash Flow-$153.7M
- Capex-$5.0K
= Free Cash Flow-$153.7M
Analysis
FY2025 free cash flow is -$153.7M. FCF conversion is 95.3% of net income. Operating cash flow was -$153.7M, with capex of -$5.0K. The largest bridge item is Stock-Based Comp at $10.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Oct 19, 2026 | |
| 8-K | Current report | Sep 24, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
Does KYTX generate free cash flow?
Kyverna Therapeutics, Inc. (KYTX) generated -$153.72M of free cash flow in fiscal 2025.
How much operating cash flow does KYTX produce?
Operating cash flow was -$153.71M, before capital expenditures of $5,000.00.
Continue the stock analysis
Jump to another research area for this company.